HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Selegiline transdermal system: a novel treatment option for major depressive disorder.

AbstractBACKGROUND:
The use of monoamine oxidase inhibitors has declined owing to the risk of hypertensive crisis following the consumption of tyramine-rich foods and the consequent need for dietary tyramine restriction. However, owing to their superior efficacy in treating depression, continued efforts have been made to develop more selective and reversible monoamine oxidase inhibitors. Oral selegiline, at low doses, is a selective monoamine oxidase B (MAO-B) inhibitor, but at higher doses it loses its selectivity and can potentially interact with tyramine. Unfortunately, antidepressant effects of selegiline have been observed only at higher doses. The selegiline transdermal system was developed to deliver sustained selegiline blood concentrations sufficient to selectively inhibit MAO-A and MAO-B in the brain, producing antidepressant effects, without substantially inhibiting MAO-A in the gastrointestinal tract, thereby reducing the risk of hypertensive crisis.
OBJECTIVES:
This article reviews the basic pharmacology, as well as efficacy and safety data of selegiline transdermal system for the treatment of depression.
CONCLUSIONS:
Selegiline transdermal system is safe and effective in treating major depressive disorder at the dose range of 6 - 12 mg/24 h, without the need for dietary precautions at the 6 mg/24 h dose. No cases of hypertensive crisis were reported in clinical trials, even without dietary restrictions.
AuthorsJayasree J Nandagopal, Melissa P DelBello
JournalExpert opinion on pharmacotherapy (Expert Opin Pharmacother) Vol. 10 Issue 10 Pg. 1665-73 (Jul 2009) ISSN: 1744-7666 [Electronic] England
PMID19527191 (Publication Type: Journal Article, Review)
Chemical References
  • AN-1792
  • Amyloid beta-Peptides
  • Selegiline
Topics
  • Administration, Cutaneous
  • Amyloid beta-Peptides (administration & dosage, adverse effects, therapeutic use)
  • Animals
  • Clinical Trials as Topic
  • Depressive Disorder, Major (drug therapy, metabolism)
  • Humans
  • Randomized Controlled Trials as Topic
  • Selegiline (administration & dosage, adverse effects, therapeutic use)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: